DSIP Guide

DSIP (Delta Sleep-Inducing Peptide) is an endogenous nonapeptide that crosses the blood-brain barrier to promote delta wave (slow-wave) sleep, reduce cortisol and ACTH levels, and provide anxiolytic effects. Originally isolated in 1974, it remains one of the most unique sleep-optimization peptides — targeting sleep architecture rather than just sleep onset.

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nine-amino-acid peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated by Swiss researcher Marcel Monnier in 1974. Monnier collected blood from rabbit cerebral veins during electrically-induced slow-wave sleep, then infused this blood into awake rabbits — which promptly fell into deep delta sleep. The active factor was isolated and named DSIP.

Unlike melatonin which signals circadian timing for sleep onset, DSIP directly promotes delta wave (Stage 3 / slow-wave) sleep — the deepest, most physically restorative stage of the sleep cycle. Delta sleep is when growth hormone is primarily released, cellular repair occurs, immune memory consolidates, and metabolic waste is cleared from the brain via the glymphatic system.

DSIP has a broad physiological profile beyond sleep: it reduces cortisol and ACTH (adrenocorticotropic hormone) secretion, blunts stress reactivity, shows antioxidant properties, and provides anxiolytic (anti-anxiety) effects in animal models. This makes it relevant for users whose poor sleep is driven by high nighttime cortisol — a common pattern in overtrained athletes, high-stress executives, and night-shift workers.

DSIP increases slow-wave (delta, 0.5–4 Hz) activity in the EEG during sleep, deepening Stage 3 sleep architecture. This is distinct from sedative sleep aids like benzodiazepines that actually suppress delta activity. DSIP promotes restorative deep sleep without next-day sedation or rebound insomnia — making it superior to pharmaceutical sedatives for sleep quality optimization.

DSIP blunts the HPA (hypothalamic-pituitary-adrenal) axis response, reducing nighttime cortisol and ACTH release. Elevated nighttime cortisol is a primary driver of poor sleep quality — causing frequent wakings, reduced delta sleep, and next-day fatigue. By reducing cortisol during sleep hours, DSIP creates the hormonal environment needed for deep, uninterrupted sleep.

DSIP is one of the few peptides that reliably crosses the blood-brain barrier after peripheral injection or even oral administration (at higher doses). Its nine-amino-acid sequence includes hydrophobic residues that facilitate membrane transport. This CNS access is what gives DSIP its direct effects on sleep regulatory centers in the hypothalamus and brain stem.

DSIP has an unusually long biological half-life estimated at 20–30 minutes for plasma clearance but with sleep-promoting effects that can persist for days after a single dose. This suggests DSIP acts as a trigger for endogenous sleep cascade mechanisms rather than simply replacing sleep signals — consistent with its endogenous nature as a self-reinforcing sleep signal.

Delta Wave Promotion: DSIP increases slow-wave (delta, 0.5–4 Hz) activity in the EEG during sleep, deepening Stage 3 sleep architecture. This is distinct from sedative sleep aids like benzodiazepines that actually suppress delta activity. DSIP promotes restorative deep sleep without next-day sedation or rebound insomnia — making it superior to pharmaceutical sedatives for sleep quality optimization.

Cortisol & ACTH Reduction: DSIP blunts the HPA (hypothalamic-pituitary-adrenal) axis response, reducing nighttime cortisol and ACTH release. Elevated nighttime cortisol is a primary driver of poor sleep quality — causing frequent wakings, reduced delta sleep, and next-day fatigue. By reducing cortisol during sleep hours, DSIP creates the hormonal environment needed for deep, uninterrupted sleep.

BBB Penetration: DSIP is one of the few peptides that reliably crosses the blood-brain barrier after peripheral injection or even oral administration (at higher doses). Its nine-amino-acid sequence includes hydrophobic residues that facilitate membrane transport. This CNS access is what gives DSIP its direct effects on sleep regulatory centers in the hypothalamus and brain stem.

Prolonged Duration: DSIP has an unusually long biological half-life estimated at 20–30 minutes for plasma clearance but with sleep-promoting effects that can persist for days after a single dose. This suggests DSIP acts as a trigger for endogenous sleep cascade mechanisms rather than simply replacing sleep signals — consistent with its endogenous nature as a self-reinforcing sleep signal.

Lower ambient light and avoid screens 1 hour after DSIP injection to support its cortisol-lowering effects. Use Shotlee to rate sleep quality each morning and track DSIP's impact over your protocol.